ProfileGDS5678 / 1441612_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 35% 34% 34% 35% 36% 35% 37% 33% 47% 34% 34% 33% 34% 34% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8236635
GSM967853U87-EV human glioblastoma xenograft - Control 22.7672734
GSM967854U87-EV human glioblastoma xenograft - Control 32.7713534
GSM967855U87-EV human glioblastoma xenograft - Control 42.7558335
GSM967856U87-EV human glioblastoma xenograft - Control 52.7612636
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8674935
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9154437
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7364433
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0862147
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7478234
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.765734
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7214833
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7740834
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7601734